Table 1 Eligibility criteria (longitudinal analysis)
| Â | Patients, n |
|---|---|
Inclusion criteria | |
 ≥ 2 claims with ICD-9 code 189.0 or ICD-10 code C64.xx for malignant neoplasm of the kidney on separate dates (≥ 30 days apart) during the index date period | 77,565 |
 First claim (ever) for a first-line mRCC agent (sunitinib, pazopanib, bevacizumab ± IFN-αa, temsirolimus, everolimus, sorafenib, axitinib, interleukin 2) occurs during the index date period, within 30 days before the first mRCC claim and up to the end of the rolling index period (patients with two different agents within 5 days of each other were excluded) | 5813 |
 Aged ≥ 18 years at index date | 5788 |
 Continuous enrollment eligibility 6 months pre-index and 6 months post-index dates with no gap | 2565 |
 Total no. of patients after applying all the inclusion criteria | 2565 |
Exclusion criteria | |
 Evidence of TCC (≥ 1 claim) from 30 days pre-index date through the entire follow-up period. TCC was identified by receipt of agent indicated for TCC | 2426 |
 ≥ 2 claims for 1 primary cancer from 6 months pre-index date through the index date (except for sites to which primary RCC commonly metastasizes, such as lung, bone, brain and liver) | 1992 |